Datroway Improves Survival in Hard-To-Treat TNBC Compared to Chemo
A recent clinical trial has found that datopotamab deruxtecan (Datroway), a targeted therapy, significantly improved survi...
Continue with Facebook
Continue with your email
Become a member to get even more